Note: Descriptions are shown in the official language in which they were submitted.
CA 03074054 2020-02-27
WO 2019/058172 PCT/IB2018/001138
1
MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE
DISORDER
CLAIM FOR PRIORITY
[001] This PCT International Application claims the benefit of priority of
U.S. Provisional
Patent Application No. 62/555,469, tiled September 7, 2017, the subject matter
of which is
incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[002] The present invention relates to use of mazindol in treatment for
opioid dependence
and substance use disorder, and a method of treatment in opioid dependence and
substance
use disorder.
BACKGROUND OF THE INVENTION
[003] Heroin is an opioid drug made from morphine which binds to u-opioid,
K-opioid
and 8-opioid receptors. Prolonged use of psychoactive substances over time may
lead to
dependence and/or substance use disorder. Psychoactive substances which are
commonly
used as recreational drugs include alcohol, cocaine, amphetamines related-
derivatives and
opioid substances. Any substance which increases pleasure-reward signaling
in the
mesocorticolimbic system of the brain may precipitate synaptic changes which
lead to long
term behavioral changes, such as addictive-type behavior.
[004] The impact of substance use disorder on society is both harmful and
costly. In
2015, substance abuse cost US society $249 billion for alcohol and $193
billion for illegal
drugs (1). These costs relate to healthcare, crime and loss of work
productivity. Specifically,
opioid overdose, abuse and dependence related behavior alone cost the US $78.5
billion in
2009 (2).
[005] Methods currently used to treat substance use disorder include
maintenance therapy
or detox whereby a substitute drug, such as methadone for heroin dependence
and addiction,
is provided. The dosage may be tapered until the substitute drug is no longer
administered.
Therapy and behavioral counselling are also used to treat substance abuse
disorders
[006] Pharmacological intervention such as the administration of a.nti-
anxiolytics and anti-
depressants may also be used as part of the treatment of substance use
disorder in order to
reduce withdrawal symptoms. Once a subject begins to abstain from or reduce
administration
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
2
of a substance, withdrawal symptoms are commonly present. Withdrawal symptoms
can be
highly uncomfortable, and in some cases, fatal. Symptoms include irritability,
anxiety,
sweating, nausea, vomiting, diarrhea, fatigue, tremors, headache, insomnia and
loss of
concentration. In severe cases, hallucinations, seizures and death are
possible.
[007] Relapse is also common in those who suffer from substance use disorder.
Relapse
occurs when a subject returns to administering the substance of abuse after a
period of
abstinence from the substance. Unfortunately, abstinence or a reduction in the
dose of a
substance can reduce a subject's tolerance to that substance, whilst the
cravings remain the
same. Therefore when relapse occurs, a subject may administer an amount which
satisfies
the craving, but may be harmful and even lethal due to reduced physiological
tolerance.
[008] Methadone is a synthetic opioid compound used as a heroin replacement
in treating
substance use disorder. However, dependency can arise and it is not uncommon
for subjects
to abuse methadone in the same way as other opioids such as heroin. Side
effects of
methadone use include anxiety, insomnia, drowsiness, nausea, vomiting,
diarrhea, respiratory
depression and hypotension. Methadone has been implicated in a number of
lethal
overdoses, especially when mixed with other drugs such as alcohol,
benzodiazepines and
cocaine.
[009] Naltrexone is a p-opioid, x-opioid and a 6-opioid receptor
antagonist. It can be
used to prevent the euphoria experienced by opioid use, and in turn eventually
reduce the
cravings in users who exhibit signs of opioid abuse. It has also been used to
treat alcohol
addiction. However, it is only recommended for use in treating substance use
disorder when
an initial period of abstinence from opioids has been achieved. This is to
avoid acute harmful
withdrawal symptoms from opioid abuse.
[010] Buprenorphine is a partial opioid agonist that relieves drug cravings
without
producing the "high" or dangerous side effects of other opioids. Buprenorphine
is also
available in combination with naloxone (an opioid antagonist) and can be taken
orally or
sublingually to avert withdrawal symptoms with naloxone.
[011] A vaccine comprising an optimized heroin-tetanus toxoid immune-conjugate
has
also been developed in order to treat opioid substance use disorder (3).
Preclinical studies
have demonstrated that this vaccine is able to reduce the euphoric effects of
heroin, thereby
suggesting it may be a viable treatment for preventing the craving aspect of
opioid addiction.
CA 03074054 2020-02-27
WO 2019/058172
PCT/I132018/001138
3
However, the vaccine is in preclinical testing and has not yet been approved
for use in
humans.
[012] Therefore, there is a need for a treatment for substance use
disorder, specifically
opioid abuse disorder, which obviates the problems associated with current
treatments such
as methadone and naltrexone administration. These problems include addiction
to the
substance which is being used to treat the substance abuse, managing
uncomfortable and
harmful withdrawal effects, and relapse. Furthermore, a treatment which is
currently
approved for use in humans and which can be administered within an acute stage
of
withdrawal would be advantageous.
[013] Mazindol has been investigated as a potential candidate in treating
cocaine addiction
(6). However, subsequent studies have reported mazindol as being ineffective
at treating
cocaine abuse and dependence (7, 8). The rate of relapse, number of days to
relapse and
cocaine use in these studies did not differ between subjects who were given
mazindol and
subjects who were given a placebo.
[014] Mazindol is a psychopharmacologic agent different from that of
currently available
wake-promoting drugs and psychostimulants and has a receptor signature and
functional
activity profile different from those of available attention
deficit/hyperactivity disorder
(ADHD) treatments such as d-amphetamine, which is a moderately potent
inhibitor of
dopamine transporter, norepinephrine transporter and vesicular monoamine
transporter 2 with
weaker affinities for serotonin transporter. Currently available
psychostimulants (e.g.
amphetamine salts) may lead to substance use disorders and discontinuation due
to a decline
in efficiency (e.g. in adults), but none of them promote a regulator effect on
opioid addiction.
[015] Use of mazindol when administered intraperitoneally (i.p.) has also
been
investigated for its effects on spontaneous pain related behaviors (12).
[016] Use of mazindol in treatment of attention deficit/hyperactivity
disorder (ADHD) has
been described in US 8293779. It is considered, in current medication
classifications, as a
psychoanaleptic and anorexigenic medication. It is currently authorized in
Argentina,
Mexico/Central America, and Japan for use in the treatment of obesity.
Mazindol is a
non-amphetamine compound because of its tricyclic chemical structure. It
offers a
pharmacological profile very close to that of amphetamines with less abuse
liability. Indeed,
mazindol is not metabolised to an amphetamine-like compound. The Met (2-(2-
Aminoethyl)-
3-( p -chlorophenyI)-3-hydroxyphthalimidine) has been identified to be the
main metabolite
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
4
of mazindol in man (Bugger et al., 1979). Met has been found to result from
the hydrolysis
of mazindol at moderate temperatures in neutral and alkaline aqueous solutions
(Nakashima
et at., 2004). Both mazindol and Met exhibit very close pharmacological
properties.
Mazindol and its metabolite act by blocking dopamine and norepinephrine
reuptake similarly
to amphetamines, but have a higher affinity for ti-opioid receptors and a
modest affinity for
x-opioid receptors.
[017] Table A discloses mazindol and Met tested at 1.0x10- 5 M and the
compound
binding calculated as a percent inhibition of the binding of a radioactively
labeled ligand
specific for each target (F,urofins CEREP, France).
[018] Table A - Test compound manufacturer information
.õ
Compound 11) Batch -FTW MW Purity I Formulation Stock
Number
Solution
Mazindol ACVH001 284.74 99.0 ' Powder 1x10.
2 M
(100028703-1) 1 I DIVISO
Mazindol ACBA416 339.26 339.26 [92.0 ,
Powder lx1042 M
metabolite IBMS
i(100028703-3)
1
...................................................................... õ1
FW: Formula Weight; MW: Molecular Weight
[019] An inhibition or stimulation of more than 50% is considered a
significant effect of
the test compounds. Fifty percent is a common cut-off for further
investigation (i.e.
determination of 1050 or ECso values from concentration-response curves).
Tables B and C
display the binding profiles for Mazindol and Met.
[020] Table B Compound Mazindol binding activity
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
= .......................................................... A' .. = =
Assay 1.0x10'
5-HT transporter(h). 99.5%
5-PrilA(h)b
5-11T7(h)b 52.9%
Dopamine transporter(h)a 98,2%
H1(h) a 75.3%
MI (h) 52.1%
M.2(hr 53.2%
(MOP) (h)b 89.90'
Norepincplarine transporter (h)a 100,4%
. --
antagonist radioligand
bagonist radioligand
[021] Table C. Compound Mazindol Metabolite binding activity
say Ox10 M -
I
transporter(h) 98.5%
5-HT1A(h)b 86.3%
Dopa.mine transporter(h)5 101%
Hi (hr 75.5%
k (KOP)'s 53.3
Ml(h)8 50,4%
p. (MOP) (h)b 87.9%
Norepinephrine transporter (hr 100.2%
'antagonist radioligand
bagoni st radioligand
[022] The results are expressed as a percent of control specific binding
obtained in the
presence of the test compounds:
Mea nfro Fi Dina irig
'X 100
.c 0 n 07ot speripc
and as a percent inhibition of control specific binding obtained in the
presence of the test
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
6
compounds:
. e s Ttia
100 ¨ .(21 ¨ x100)
= .40.n.4r.ci..i:.4-p.,,,i.cvic-4?Indf?kv
[023] The 1050 values (concentration causing a half-maximal inhibition of
control
specific binding) and Hill coefficients (nH) were determined by non-linear
regression
analysis of the competition curves generated with mean replicate values using
Hill equation
curve fitting:
A-D ..
1140.4)611
[024] where Y = specific binding, A ¨ left asymptote of the curve, D =
right asymptote of
the curve, C ¨ compound concentration, C50 ¨IC50, and nti = slope factor. This
analysis
was performed using software developed at Cerep (Hill software) and validated
by
comparison with data generated by the commercial. software SigmaPlo=t 4.0 for
Windows
(0 1997 by SPSS Inc.).
[025] The inhibition constants (Ki) were calculated using the Cheng Prusoff
(1973)
equation:
.1t4
IV- = _____
ottAti).
[026] where L = concentration of radioligand in the assay, and KD ¨
affinity of the
radioligand for the receptor. A scatchard plot was used to determine the KD.
[027] In addition, in animal toxicology studies, the toxic potential of
mazindol has proved
to be very low. In particular, no carcinogenic effect, no mutagenic effect,
and no toxicology
effect in reproduction was observed. In US 8,293,779, it is disclosed that,
after single or
repeated oral administration, mazindol is absorbed with a time to maximum
concentrations
(Tmax) of 2-4 hours. The half-life time of mazindol after an immediate release
formulation
is 9.1 1.7h in healthy volunteers (Kim 2009); therefore, steady-state
concentrations are
reached after approximately 30-55 hours. The pharmacokinetics is linear
(independent of the
dose) between 1 mg/day and 4 mg/day. This result however relates to current
immediate
release formulations of mazindol. Immediate-release pharmaceutical
compositions of
mazindol, such as Diminex , Sanorex and Teronac , ensure the release of the
active
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
7
ingredient over a period of <1 h in vitro. Indeed, immediate-release
pharmaceutical
compositions of mazindol have been reported to undergo hydrolysis at moderate
temperatures
in neutral and alkaline aqueous solutions, including in human plasma. Due to
the mild
alkaline nature of plasma, improved mazindol stability in human plasma is
achieved by
adding acidic buffer.
[028] To achieve once daily dosing regimen (a very desirable regimen for
compliance), a
better controlled release portion would also be needed to assure that adequate
plasma
concentrations are achieved throughout the day and evening, while also
allowing the subject
to fall asleep and remain asleep during the night. Thus, there is a need for a
pharmaceutical
composition with an improved release profile of active substance combining an
immediate
and a sustained release, an improved compliance for patients, and reduced
fluctuation in
steady-state plasma concentrations during a dosing interval, for treatment of
a substance use
disorder.
[029] The above mentioned problems have been solved by the aspects and
embodiments
of the present invention outlined below.
SUMMARY OF THE INVENTION
[030] The present invention provides mazindol for use in the treatment of
substance use
disorder, Preferably, the substance is an opioid.
[031] The present invention also provides a method of treatment of
substance use
disorder, wherein the substance is an opioid, comprising administering
mazindol to a subject.
[032] The present invention also provides a composition comprising mazindol
for use in a
method of the treatment of opioid abuse disorder or pain, when in the form of
a multi-layer
matrix type tablet comprising:
[033] at least one immediate-release (1R) layer comprising mazindol and at
least one
diluent, and
[034] at least one sustained release (SR) layer comprising mazindo,1 and at
least one
sustained release, pH independent and water-insoluble polymer.
[035] in accordance with the present invention, mazindol is effective at
treating opioid
substance use disorder by reducing both opioid rewarding effect and withdrawal
symptoms.
[036] A bilayer tablet comprising mazindol which exhibits an improved
release profile is
described in Application No. 62/305,600 and PCTIEP2016/055048, which are
hereby.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
8
incorporated by reference in their entirety. The oral pharmaceutical unit
dosage form of
mazindol in the form of a multilayer matrix-type tablet of the invention
provides a rapid
release portion to provide a continual release of mazindol available for
absorption into the
patients' blood stream to achieve a prolonged therapeutic effect. This
combination can thus
achieve a once daily regimen for the product. This therefore has the following
advantages:
[037] ¨ Ease of swallowing;
[038] ¨ Ease of manufacture;
[039] ¨ The ability to control the release rate of the drug by modifying
the
components of each separate layer;
[040] ¨ Superior stability compared to other dose forms, such as
capsules, liquids;
[041] ¨ Prevents patient tampering with the dose form;
[042] ¨ Reduced fluctuation in steady-state mazindol plasma
concentrations during a
dosing interval;
[043] ¨ Enhanced stability;
[044] ¨ Onset within 1-2 hours, while not unnecessarily delaying
consumption of
food; and
[045] Muted increase in heart rate.
BRIEF DESCRIPTION OF THE FIGURES
[046] Figure 1 shows (higher panel) and compares (lower panel) the distance
travelled in
a vehicle-paired (V) and in a drug-paired (D) compartment after administration
with a
control, mazindol or amphetamine in mice.
[047] Figure 2 shows (higher panel) and compares (lower panel) the time
spent in the
vehicle-paired and in the drug-paired (D) compartment after administration
with a control,
mazindol or amphetamine in mice.
[048] Figure 3 shows the total distance travelled in both vehicle-paired
(V) and drug-
paired (D) compartments after administration with a control, mazindol or
amphetamine in
mice.
[049] Figure 4 shows the overall global score of withdrawal symptoms after
administration with a control, mazindol or amphetamine in rats subjected to
Naloxone
precipitated withdrawal syndrome of heroin.
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
9
[050] Figure 5 shows scores for weight loss (upper panel), for escape
attempts (middle
panel) and for wet dog shakes (lower panel) after administration with a
control, mazindol or
amphetamine in rats subjected to Naloxone precipitated withdrawal syndrome of
heroin.
[051] Figure 6 shows scores for diarrhea (upper panel), facial
fasciculation or teeth
chattering (middle panel) and profuse salivation (lower panel) after
administration with a
control, mazindol or amphetamine in rats subjected to Naloxone precipitated
withdrawal
syndrome of heroin.
[052] Figure 7 shows (top left panel) and compares (top right panel) the
distance travelled
in the vehicle-paired (V) and in the drug-paired (D) compartment (left panel)
after
administration with a control, heroin or mazindol in mice. The lower panel
shows (lower left
panel) and compares (lower right panel) the time spent in the vehicle-paired
(V) and in the
drug-paired (D) compartment after administration with a control, heroin or
mazindol in mice.
DETAILED DESCRIPTION OF THE INVENTION
[053] Mazindol (5-(4-chloropheny1)-2,5-clihydro-3 H-imadazo[2,1-alisoindo1-
5-01) has the
following chemical formula:
(re'
i
N I
HO ,
I
[054] The term "substance use disorder" as used in the present application
refers to any
stages associated with administration of, addiction to and withdrawal from a
substance of
abuse. This includes craving a substance, administering the substance and
experiencing
euphoria (a high), contentment or relaxation. When abstinent from the
substance the subject
may experience irritability, anxiety, sweating, nausea, vomiting, diarrhea,
fatigue, tremors,
headache, insomnia, loss of concentration, hallucinations, seizures and
increased cravings.
These are also known as withdrawal symptoms.
1:0551 The term "dependence" as used in the present application refers to
any stages
associated with prolonged use of a substance of use. This can include stages
within the term
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
"substance use disorder" and may include craving a substance, administering
the substance in
order to reduce or stop the craving, and when abstinent from the substance the
subject may
experience any of the above withdrawal symptoms.
[056] A subject with a substance use disorder may or may not be exhibiting
behaviour
associated with abuse and dependence.
[057] Substances of abuse and dependence include, but are not limited to,
opioids (such as
heroin, opium, morphine, buprenorphine, codeine, fentanyl, hydrocodone,
methadone,
tramadol, and any naturally occurring or synthetic derivatives or related
compounds thereot)
alcohol, cocaine, crack cocaine, amphetamines, methamphetamines,
benzodiazepines, GI-IB
and nicotine.
[058] A subject may be using, or addicted to, more than one opioid or other
substances of
abuse and dependence simultaneously.
[059] The use of the compounds and compositions of the present invention
are suitable for
all mammals and particularly humans.
[060] Mazindol may be used simultaneously alongside other treatments for
substance use
disorder, such as methadone, buprenorphinelnalexone, and/or naltrexone
administration, anti-
anxiolytic administration and counselling.
[061] The present invention also provides mazindol for use in the treatment
of pain,
preferably rheumatic pain. The pain may be neuropathic or nociceptive pain.
The pain may
be acute or chronic.
[062] Mazindol is preferably administered to a subject orally in the form
of a tablet or
capsule. Mazindol may also be administered or used as a liquid or powder
formulation. The
administration of or use of mazindol may be wherein mazindol is suitable for
injection or
inthsion, via an intravenous, subcutaneous, subdermal, intraperitoneal or
intraocular route.
Mazindol is preferably administered in a formulation with a sustained release,
such as the
bilayer tablet described herein.
[063] The tablet, or oral pharmaceutical unit dosage form, in preferably in
the form of a
multilayer matrix-type tablet can provide a rapid release of drug to achieve a
rapid
therapeutic blood level and a sustained release portion to provide a continual
release of
mazindol available for absorption into the patients' blood stream to achieve a
prolonged
therapeutic effect.
CA 03074054 2020-02-27
WO 2019/058172
PCT/I132018/001138
11
[064] The term "matrix-type tablet" is used in the invention to designate a
tablet whose
inner structure in each layer is homogeneous and identical from the center
towards the
periphery of the layer. Therefore, the layers of the tablets of the present
invention consist of
a homogeneous mixture of active ingredient in powder or granule form and of a
compression
matrix.
[065] An "immediate-release (IR) layer" refers to a layer that releases
greater than or
equal to about 80% by weight of mazindol in less than or equal to about 1
hour. A
"sustained-release (SR) layer" means a layer in which mazindol is released at
a rate slower
than that of an IR layer. The ratio in weight between the IR layer/s and the
SR layer/s of such
a tablet is preferably between 40:60 and 80:20, more preferably between 50:50
and 70:30,
most preferably 50:50.
[066] A process for preparing the tablet may comprise the following steps:
[067] (a) preparing a blend of IR layers
[068] (b) preparing a blend of SR layers
[069] (c) adding the IR blend of step (a) and the SR blend of step (b) into
a multilayer,
preferably a bilayer, tablet press.
[070] Mazindol for any of the embodiments described above may also be provided
in a
composition comprising additional components including a pharmaceutically
acceptable
carrier or excipient, or diluent.
[071] Examples of diluents include: lactose, monohydrate lactose, anhydrous
lactose,
spray-dried lactose, calcium carbonate, calcium sulfate, calcium sulfate
dehydrate, calcium
lactate trihydrate, monobasic calcium sulfate monohydrate, calcium carbonate,
tribasic
calcium phosphate, diabasic calcium phosphate, compressible sugars, dextrates,
dextrin,
dextrose, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide,
maltodextrin,
mannitol, powdered cellulose, starch, modified starch, starch hydrolyzates,
pregelatinized
starch, microcrystalline cellulose, powdered cellulose, cellulose and
cellulose derivatives,
hydroxypropylmethylcellulose, hydroxypropylmethylcellulose and sucrose,
preferably
lactose, anhydrous lactose, spray-dried lactose, microcrystalline cellulose,
powdered
cellulose, cellulose and cellulose derivatives.
[072] Diluent concentration in the composition or IR layer of a multilayer
tablet can be
varied between 1 and 95%, preferably 30 and 60%, more preferably 45 to 55% by
weight of
the total weight of the composition, or the IR layer in a multi-layer matrix
type tablet.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
12
[0731 Preferably, a unit dosage form according to the invention comprises a
lubricant in
the composition or tablet layer. Lubricants and glidants can be employed in
the present
invention to prevent, reduce or inhibit adhesion or friction of ingredients of
the composition.
They facilitate the compression and ejection of compressed compositions from a
desired die.
They are compatible with the ingredients of the pharmaceutical composition,
and they do not
significantly reduce the solubility, hardness, chemical stability, physical
stability, or the
biological activity of the pharmaceutical composition. The pharmaceutically
acceptable
lubricants and glidants for the present invention are selected from the group
including but not
limited to stearic acid, metallic stearates, zinc stearate, magnesium
stearate, magnesium
trisilicate, calcium hydroxide, tribasic calcium phosphate, magnesium
carbonate, magnesium
oxide, calcium stearate, glyceryl monostearate, waxes, glycerides, glyceryl
behenate, glyceryl
palmitostearate, silicone oil, hydrogenated vegetable oil, hydrogenated castor
oil, light
mineral oil, mineral oil, polyethylene glycol, methoxypolyethylene glycol,
sodium acetate,
sodium oleate, sodium chloride, leucine, sodium benzoate, alkyl sulfates,
sodium lauryl
sulfate, sodium stearyl fumarate, talc, colloidal silica, corn starch,
powdered cellulose, and/or
boric acid. The preferred range of lubricants/glidants is from 0% to I % w/w
of the
composition or tablet layer.
[074] Sustained-release, pH-independent and water-insoluble polymers can
also be used
in the composition or SR layers of the tablets according to the invention is
selected in the
group consisting of cellulose polymers, high-molecular-weight polymers of
acrylic acid that
are crosslinked with either allyl sucrose or allyl ethers of pentaerythritol
(Carbopol,
Carbomers), polymers from the class of methacrylic acids, polyvinylalcohol
derivatives,
polymers of lactic and glycolic acids (PLGA), starches, waxes, polyvinyl
acetate derivatives,
polyvinyl pyrrolidone derivatives and mixtures thereof, preferably is selected
in the group
consisting of cellulose polymers and high-molecular-weight polymers of acrylic
acid that are
crosslinked with either allyl sucrose or allyl ethers of pentaerythritol
(Carbopol, Carbomers).
Cellulose polymers include hydroxypropyl methylcellulose (HPMC), hydroxypropyl
cellulose (HPC), sodium CMC, ethyl cellulose derivatives such as cellulose
acetate, cellulose
acetate butyrate, cellulose acetate cellulose propionate,
hydroxypropylmethylcellu lose acetate
succinate, microcrystalline cellulose (for example such as the one supplied
under the trade
mark Avicela, and ethylcellulose (for example the one supplied under the trade
mark
Aqualong ethylcellulose).
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
13
[075] Polymers from the class of methacrylic acids include the grades
EudragiteRL 12.5,
RL PO and RL 100 and RS 12.5, RS PO and RS 100. Starches include natural
starches e.g.
corn starches and modified starches such as pre-gelled starch. Waxes include
white or yellow
beeswax, polyvinyl acetate derivatives.
[076] Sustained-release, pH-independent and water-insoluble polymer
concentration in
the composition or SR layers of a multilayer tablet can be varied between 80
and 99%,
preferably 90 to 97% by weight of the total weight of the composition or SR
layers.
[077] The tablet form according to the invention can include anti-
agglomerant agents.
Anti-agglomerant agents used in the present invention include talc, silicon
dioxide and its
derivatives, acrylic esters, castor oil derivative, cellulose compounds, iron
oxides, magnesium
stearate, stearic acid and or sodium stearate.
[078] Layers of a tablet according to the present invention can comprise a
binder. Binders
according to the invention, include hydroxypropylmethylcellulose (HPMC),
hydroxypropylcellulose (HPC), maltodextrin, polyvinylpyrrolidone (PVP) and or
microcrystalline cellulose.
[079] As described herein, a controlled release formulation of mazindol is
provided
containing immediate and sustained release layers in a layered tablet, which
when ingested
leads to an initial burst of mazindol followed by a slower, continual release,
for example,
over 6-8 hours (from ingestion) where it can be dissolved and absorbed in the
small intestine,
before it reaches the colon.
[080] The initial availability of mazindol is advantageous for patients
because they need a
sufficient drug levels at the beginning of their day. Subsequently, the slower
continual
release and absorption of mazindol in the intestine provided by the
formulation of the present
invention assures that adequate plasma concentrations are achieved throughout
the day and
evening, while allowing the subject to fall asleep and remain asleep during
the night.
[081] Mazindol or a composition comprising mazindol, while not especially
limited can
be administered daily to a subject. A daily dosage may range from 0.25 mg to
16 mg,
preferably 1 to 9 mg and more preferably 1 mg to 3 mg.
[082] The present invention will now be illustrated, but in no way limited,
by reference to
the following examples.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
14
EXAMPLES
[083] Conditioned place preference (CPP) is a widely used procedure for
studying the
potential addictive effect of drugs. CPP is based upon the tendency of rodents
to approach a
stimulus that has previously been paired with an incentive state induced by a
drug. A drug
that induces a CPP may be suspected to present reinforcing effects that could
lead to
addiction. Numerous addictive drugs, such as opiate agonists or stimulants
induce a CPP and
a behavioral sensitization.
[084] The abrupt cessation of chronic opiate use results in a well
characterized withdrawal
syndrome with symptoms that include pain sensitivity, dysphoria, irritability,
restlessness,
insomnia, diarrhea and hyperventilation. In the present model, the naloxone-
precipitated
withdrawal syndrome is measured in rodents. Animals are chronically treated
with a drug,
e.g. morphine or heroin. Opiate withdrawal syndrome is elicited by an acute
injection of the
opiate antagonist Naloxone.
110851 Past studies using similar experimental procedures have shown that
morphine
induced place preference in C57BL./6J mice and opioid withdrawal syndrome
following
naloxone injection in Sprague-Dawley rats.
[086] The effect of mazindol on place preference was examined in C57BL/6i
mice using a
method similar to the one used by Schlussman et al. (9).
[087] The effect of mazindol on heroin withdrawal syndrome elicited by
naloxone was
examined in Sprague-Dawley rats using a method similar to the one used by
Jiang et at. (10),
[088] In the present study, the effect of mazindol was compared with those
of
methylphenidate and D-amphetatnine.
(089] Here, mazindol has been tested in two rodent models which account for
two
components of addiction, the CPP paradigm which is widely used to measure the
rewarding
effect of a drug, and the heroin withdrawal symptoms precipitated by naloxone.
These two
components, the rewarding effect and the withdrawal symptoms, contribute to
the craving for
drug of abuses such as heroin.
[090] The study included five experiments. The first four experiments were
performed on
mice. The fifth experiment was performed on rats. The first experiment
consisted in
determining the doses of mazindol, D-amphetamine and methylphenidate which are
devoid of
significant motor effects that might disrupt the measure of place preference.
For this purpose,
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
the effects of mazindol and D-amphetamine on spontaneous locomotor activity
were
examined in mice.
[091] The second experiment consisted in determining the optimal dose of
heroin which
induces the most significant CPP. For this purpose, the CPP induced by heroin
at 1.25, 2.5
and 5 mg/kg was examined.
[092] The third experiments consisted in examining the effects of' mazindol
and D-
amphetamine (at doses chosen from results of the first part of the study) on
the place
preference induced by heroin at a dose chosen from results of the second
experiment, which
was 1.25 mg/kg. Mazindol (0.125, 0.25 and 0.5 mg/kg) and D-amphetamine (0.5
mg/kg)
were tested.
[093] The results of experiment 3 showed that mazindol (0.25 and 0.5 mg/kg)
tended to
reduce the place preference induced by heroin. Therefore, it was decided to
perform an
additional experiment to examine the effects on place preference induced by
heroin of
mazindol at 1 and 2 mg/kg and of D-amphetamine at 1 mg/kg. It was also decided
to
examine in the same experiment whether mazindol (2 mg/kg) induced a place
preference.
[094] The fifth experiment consisted in examining the effects of mazindol
and 1)-
amphetamine on physical heroin withdrawal symptoms induced by naloxone.
[095] The first experiment led to select the doses of 0.125, 0.25 and 0.5
mg/kg for
mazindol and the dose of 0.5 mg/kg for D-amphetamine. It also led to choose
pretreatment
times of 60 min for mazindol and 30 min for D-amphetamine.
[096] The second experiment showed the heroin induced CPP at the three doses
tested and
that 1.25 mg/kg was suitable to examine the effects of treatments on CPP.
[097] The third and fourth experiments showed that mazindol (0.25, 0.5 mg/kg),
but not
D-amphetamine (0.5, 1 mg/kg), decreased the place preference induced by
heroin.
[098] The fifth experiment showed that mazindol at doses of 0.25, 0.5, 1 and 2
mg/kg
reduced the withdrawal symptoms of heroin. In contrast, D-amphetamine (1
mg/kg) was
ineffective to reduce withdrawal symptoms of heroin.
[099] The results of the present study have unexpectedly shown that mazindol,
but not D-
amphetamine, decreased the place preference induced by heroin and reduced the
withdrawal
symptoms of heroin. These results show that mazindol, but not D-amphetarnine,
is an
effective treatment of heroin addiction by reducing both the rewarding effect
and the
withdrawal symptoms of heroin.
CA 03074054 2020-02-27
WO 2019/058172 PCT/IB2018/001138
16
[0100] Manipulations of animals were conducted carefully in order to reduce
stress at the
minimum. All the experiments were performed in compliance with the guidelines
of the
French Ministry of Agriculture for experiments with laboratory animals (law
2013-118). The
experimental protocol and euthanasia have been approved by the Ethical
Committee 27,
registered at the French ministry of research. Experiments were conducted
during the light
phase in standard conditions (T'= 22.0 1.5 C) with artificial light in quiet
conditions (no
noise except those generated by ventilation and by the apparatus used for
experiments). The
animals were not subjected to other experiments before the study. Animals were
not placed
in enriched environment that might modify their behavior and the effects of
drugs. Each
animal was identified with a bar code marked on the tail.
. .............. = " . ......... . .
Mazindni 5-(4-01 I oropheny1)-2,5-d ihydro-3H-irnidazo1.2,1-a]
isoindol-5-ol
== ................... . ..........
Vehicle Dissolution in 0.1N HC, then diluted with 0.9% Naa
(solution: pH 6)
= .......................................................... = .. .õ.
. . =
Administration route Intra-peritoneal (i.p.)
. .
Doses studied (rrigikg) Ø125,.Ø25., 0.5, 1,2
.............................................. = = . __ ' ....... = =
=
'Correction factor (e.g. 1
salt/base ratio)
= . ................ " " =
'Number of administration 1 =
Application volume 110 (mice) or 2 (rats) ml/kg of body weight: --
. .
....... . .
Preparation jTfltions .. were prepared every week
== .... . .. . .... .
'Storage cOnditions During tests: less than 4 h, ambient temperature (22-23
C), protect. from
light
=
Between tests 4 C, protect from light
= = =
pH
6
,,,,,, =======,,,,,, = = = = = = = = - ,,,,,,,,, .......... .... =
,,,,,,,,, = = ===================,
Appearance of solution Clear, colourless, coinpletely dissolved.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
17
Methylphenidate ' Metitylphenidate hydrochloride
Supplier Sigma, France
Vehicle Dissolved in 0.9% NaCI
' ......................................
' Administration route i.p,
................................................. --õ. ________
Doses studied (mg/kg) 025,05, 1,2
Correction factor (salt/base (dose expressed as salt)
ratio)
Number of administration 1
_
Application volume 10 mlfkg of body weight.
Preparation The solutions are prepared extemporaneously
Storage conditions Less than 4 h, ambient temperature (22-23cC), protect
from light
Pli 6
Appearance of solution Clear, colourless, completely dissolved.
_________________________________ õ . ........
D-anaphetamitte D-amphetamine sulfate
Supplier Sigma, France
Code number A5880
Batch number 058K3350
VehiCie Dissolved in 0..9% NaCI
, ...........................
Administration route 1,p,
Doses studied (mg/kg) 0.125, 0,25, 0,5, 1
..................................................................... =
Correction factor (salt/base I (dose expressed as salt)
ratio)
õ
Number of administration 1
s s
Application volume 10 ini/kg of body weight.
Preparation The solutions are prepared extemporaneously
H.Storage conditions Less than 4 h, ambient tcrnperature (22-23'C), protect
from light
ofi to
Appearance of solution Clear, colourless, completely dissolved.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
18
i Heroin
.õ
: Supplier ===== = S igrna, France
Vehicle Dissolution in 0,9% NaC1
. ................. = .. =
= i'vu nu1 I stration route
. .................................................................. .
Doses studied (mg/kg) 1,25, 2.5, 5 mg/kg (mice, CPP test); 3, 6, 9, 12, 15,
18, 21, 24, 27,
30 mg/kg (rats, withdrawal test)
......................................... . . .
Correction factor (e.g. 1
salt/base ratio)
..................................... ,
Number of administration 4 (mice, CPP test), 25 (rats, withdrawal test)
Application voiume 10 (mice) or 1 (rats) ml/kg of body weight.:
. Preparation The solutions are prepared extemporaneously
.
Storage conditions Less than 4 hõ ambient temperature (22-23 C) protect
from light :
.................................................. = ,,,,,,,, __
. . ........... .
pH 6
, . . ---------------- . = _ . ..
Appearance of solution Clear, colourless, completely -dissolved.
. . __________________________ . .
'Effects of nita.KindoI 10.125-0,5 uktikg) and of D-atntdactainino (9+5
au;s1R0 aa the pivRtOS
preference induced...bv ifteroin and determination of the place preference
induced by
mazindul (2 mg/kg)
[0101] The experimental design is shown in Table 1. Following the habituation
session (on
day 1), animals (N¨ 72) were pseudo-randomly assigned to two groups, a Control
group (N=
12) and a Heroin group (N= 60), in a way that there was no significant
difference between the
two groups for the total distance travelled in the apparatus and for the
percentage of time
spent and the percentage distance travelled in the grey compartment and in the
striped
compartment.
[0102] Animals received the fbIlowing treatments immediately before drug
sessions:
[01031 - Control group: vehicle
[0104] - Heroin group: heroin (1.25 mg/kg)
[0105] Following the last conditioning session, the Heroin group was pseudo-
randomly
divided into 5 groups (N= 12/group) in a way that there was no significant
difference
between groups for the total distance travelled in the apparatus and for the
percentage of time
spent and the percentage distance travelled in the grey compartment and in the
striped
compartment in habituation session, for the distance travelled in the drug-
paired and in the
CA 03074054 2020-02-27
WO 2019/058172
PCT/I132018/001138
19
vehicle-paired compartments in conditioning sessions and for the proportion of
striped drug-
paired compartments.
[0106] Animals received the following treatments before preference session:
[0107] - Control group: vehicle of mazindol, i.p. 60 min before testing.
[0108] - Hero group: vehicle of mazindol, i.p. 60 min before testing.
[0109] - Hero-A 0.5 group: D-amphetamine (0.5 mg/kg), i.p. 30 min before
testing.
[0110] - Hero-Mz 0.125 group: mazindol (0.125 mg/kg), i.p. 60 min before
testing.
[0111] - Hero-Mz 0.25 group: mazindol (0.25 mg/kg), i.p. 60 min before
testing.
[0112] - Hero-Mz 0.5 group: mazindol (0.5 mg/kg), i.p. 60 min before
testing.
[0113] Table 1 - treatments (in mg/kg) administered in each session (Maz:
mazindol, D-A:
D-amphetamine). Within each group, drug sessions were conducted on even
sessions and
vehicle sessions were conducted on odd sessions for half of animals and vice
versa for the
other half of animals.
; Group N Days
.................................................................... -
d01 l d02 d03 1 d04 1 d05
d08 1 d09 d10 d12
. = .. ...... .4 .. . .. .
Habituati- Conditioning sessions ;
Preference
on sess. session
Si 1 S2 S3 S4 S5 I S6 :1 S7 S8
Control 12 : No ]- Drug sessions: vehicle / Veh sessions: vehicle
Vehicle
................................ == -
treatment
Hero 12 Drug sessions: heroin 1.25 Vehicle
Hero-A 0.5 12 Vehicle sessions: vehicle D-A 0.5
........... ,,,,
1-Tero-Mz 12 1 Maz 0.125
0.125
Hero-Mz 0.25 ; 12 Maz 0.25
Hero-Mz 0.5 12 Maz 0.5 [
=
EtTeCts ofimazindol ft 2 Mg /141 and of Dilughetaitthle.I aiwkg1 on The
.place.weierence
induced by heroin.
[0114] The experimental design is shown in Table 2. Following the habituation
session (on
day 1), animals (N= 72) were pseudo-randomly assigned to three groups, a
Control group
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
(N= 12), a Heroin group (N= 48) and a Mazindol group (N = 12), in a way that
there was no
significant difference between the three groups for the total distance
travelled in the apparatus
and for the percentage of time spent and the percentage distance travelled in
the grey
compartment and in the striped compartment.
[0115] Animals received the following treatments before drug sessions:
[0116] - Control group: vehicle, i.p. immediately before session.
[0117] - Heroin group: heroin (1.25 mg/kg), i.p. immediately before
session.
[0118] - MAZ 2 group: mazindol (2 mg/kg), i.p. 60 min before session.
[0119] Following the last conditioning session, the Heroin group was pseudo-
randomly
divided into 4 groups (N= 12/group) in a way that there is no significant
difference between
groups for the total distance travelled in the apparatus and for the
percentage of time spent
and the percentage distance travelled in the grey compartment and in the
striped compartment
in habituation session, for the distance travelled in the drug-paired and in
the vehicle-paired
compartments in conditioning sessions and for the proportion of striped drug-
paired
compartments.
[0120] Animals received the following treatments before preference session:
[0121] - Control group: vehicle of mazindol, i.p. 60 min before testing.
[0122] - Hero group: vehicle of mazindol, i.p. 60 min before testing.
[0123] Hero-Mz 1 group: mazindol (1 mg/kg), i.p. 60 min before testing.
[0124] - Hero-Mz 2 group: mazindol (2 mg/kg), i.p. 60 min before testing.
[0125] - Hero-A I group: D-amphetamine (1 mg/kg), i.p. 30 min before
testing.
[0126] - MAZ 2 group: vehicle of mazindol, i.p. 60 min before testing.
[0127] Table 2 - treatments (in mg/kg) administered in each session. Within
each group,
drug sessions were conducted on even sessions and vehicle sessions were
conducted on odd
sessions for half of animals and vice versa for the other half of animals.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
21
1 Group N Days
_____________________________________________________________ i =
d01 d02 d03 d04 d05 d08 d09 . di 0 t di 1 d12
........................................ . õ,, . = õ .....
.. = ..
Habituation I Conditioning session Preference
session session
Si r S2 S3 S4 S5 S6 S7 S8
Control 12 No Drug sessions: vehicle Veh sessions: vehicle
Vehicle
........... ....
' treatment
Hero
12Drug sessions: heroin 1.25 : Vehicle
.... ====
Hero-Mz I 12 Vehicle sessions: vehicle Mazindol 1
Hero-Nelz 2 12 LMaz1ndo12
, . .
.
=
Hero-A 1 12 D-amphet
1V1AZ 2 12 Drug sessions: mazindoi 2 / Veh sessions: Vehicle
.1 vehicle =
.Naloxone:amighoted ithdrawasyndrome .,(4 heroin
[0128] In the protocol planned before, it was planned to follow the method
used by Jiang et
al. Mice had to receive two subcutaneous injections/day of heroin at
increasing doses (3 to
30 mg/kg) for 9 consecutive days and a single injection on the 10th day. This
procedure led to
a substantial mortality from the first days of treatment. It is likely that
the discrepancy of
toxicity between our experiments and the study of Jiang et al. partly resulted
from difference
in purity of heroin. Therefore, it was necessary to develop a method allowing
to observe
clear withdrawal symptoms and an acceptable mortality rate. This method is
presented
below, For information, 178 rats, including those used for the development of
the method,
have been used for this study of which 54 have been included in the results
presented here.
[0129] Animals were subdivided into two groups. One group received heroin two
i.p.
injections/day for 12 consecutive days and a single injection on the 13th day
(total: 25
injections) as exposed in Table 3 group received saline instead of heroin
following the same
protocol.
[0130] Table 3 - doses of heroin administered i.p. from day I until day 13
CA 03074054 2020-02-27
WO 2019/058172
PCT/1B2018/001138
22
;2 injections/day at 9pm and 17 pm I
injection
(9-11 pin)
Days dl d2 d3 d4 d5 d6 d7 d8 d9 d10 dl 1 d12 d13
Doses (rogikg) 2 3 3 5 5 7 7 9 9 11!13 15
15
=
[0131] On day 13, animals received treatments and were tested according to the
following
time schedule:
[0132] T = 0: i.p. injection of heroin (15 mg/kg) or vehicle.
[0133] T = 2.5h: animals individually placed in a transparent Plexiglas
observation
boxes (40 x 40 x 40 cm).
[0134] - T = 3.5h: i.p. injection of treatment (see below).
[0135] - T = 4h: i.p. injection of naloxone (5 mg/kg), start of test:
observation of
withdrawal symptoms as indicated in Table 4.
[0136] T = 5h: end of test, animals placed back into their home cages.
[0137] Animals received the following treatments at T 3.5h (i.e. 30 min before
injection of
naloxone and observation of symptoms):
[0138] 1) Animals treated with saline during the intoxication period (days
1-12) and at
TO on day 13:
[0139] - Saline group (N = 8): saline (0.9% NaC1).
[0140] 2) Animals treated with morphine during the intoxication period
(days 1-12) and
at TO on day 13:
[0141] - Hero group (N= 14): saline (0.9% NaCl).
[0142] Amph 1 group (N = 4): 13-amphetamine (1 mg/kg).
[0143] Maz 0.125 group (N = 5): mazindol (0.125 mg/kg).
[0144] - Maz 0. 25 group (N = 6): mazindol (0.25 mg/kg).
[0145] - Maz 0. 5 group (N = 6): mazindol (0.5 mg/kg).
[0146] Maz 1 group (N = 6): mazindol (1 mg/kg).
[0147] Maz 2 group (N = 5): mazindol (2 mg/kg).
[0148] The withdrawal symptoms recorded are presented in Table 4. A weighting
factor
was ascribed for each sign from which a score was calculated.
[0149] Examples:
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
23
[0150] - Body weight before naloxone injection = 241g; after naloxone
injection=
236g:
[0151] 0 Weight loss score¨ 2 ¨ 100 x (241 ¨ 236)/241
[0152] - Number of escape attempts = 8:
[0153] o Score for escape attempts = 2
[0154] - Profuse salivation present:
[01551 o Score for profuse salivation
[0156] A global withdrawal score was then calculated:
[0157] - Global score = the sum of the scores
[0158] Table 4 - Withdrawal symptoms recorded and Gellert-Holtzman rating
scores (11)
................... =õ ...................... . ...... ¨ I=
weight31-8 .
Symptoms Number or frequency of measures Units
= : l factor
............................................ - .. .._ ...
Graded signs
-= . .. . . ................... :,
Body weight is measured before and For each I% I
Weight loss :.. I
2.5h after naloxone injection . weight lost 1 ':
, .. _ õ __ .... , _ =. v. .
: 2-4 ., 1
.................................................. -,¨ i
Nb of escape attempts 5-9 i 4:..,
1 0 or FROM I 3¨
Nb of abdominal Co inted on the six I 0-inin periods .. 1
Each one
constrictions l
3 ................................................. =", I 2
1- ................................................
. Nti of wet dog shakes .
õ
3 Of more. 1 4
Checked signs ¨ Noted simply as bel g present or absent
................... T ........................... ---, ,
Diarrhea If pr...fient 2
..
. Facial fascientations or teeth
= If present i 2
: chattering
- ¨ ..................................................................
Swallowing movements : If present 1
.1 .,..
Profuse salivation 1 Counted once during the whole 61)- . If pres 7 ent
.
1
, ....................................................
.. ................ :
Cnromoclacryorritc.a I min session If present 1 5
Ptosis - .7----.:-- .......................................... .
If present
....-
Almiormal POSEUR: If present:13
Erection or ejaculation If pres.ent :
: .
: 11.6:lability If present I 3
..:,
,
........................................................ , _
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
24
EffwAoffmizindol .and of altnialfettamiiie On tholaCe preference induCed bv
beroiri*nd
determination of the place preference induced by mazindol
[0159] The results of the preference session are presented in Table 5.
.Effect of heroin
101601 Heroin (1.25 mg/kg), administered before drug sessions induced the same
effects at
the preference session.
[0161] - An increase of the difference of distance travelled in the
drug-paired vs. the
vehicle- paired compartment:
[0162] 0 In the
Hero group, but not in the Control group, the distance
travelled was higher in the drug-paired compartment than in the
vehicle-paired compartment (Figure 1, upper panel).
[0163] o The
difference of distance travelled in the drug-paired vs. the
vehicle-paired compartment was higher in the Hero group than in
the Control group (Figure 1, lower panel).
[0164] - An increase of the time spent in the drug-paired vs. the
vehicle-paired
compartment:
[0165] a In the
Hero group, but not in control group, the time spent was
higher in the drug- paired compartment than in the vehicle-paired
compartment (Figure 2, upper panel).
[0166] a The
difference of time spent in the drug-paired vs. the vehicle-
paired compartment was higher in the Hero group than in the
Control group (Figure 2, lower panel).
[0167] - No significant modification of the total distance travelled in
two
compartments (Figure 3).
[0168] Conclusions: Heroin (1.25 mg/kg) induced a place preference.
[0169] Heroin (1.25 mg/kg) dramatically increased the distance travelled in
the drug-paired
compartment comparatively with the vehicle-paired compartment at the
preference session
and more modestly but significantly increased the time spent in the drug-
paired compartment.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
Effect .of D-amphetainine On place: preference tatinced by ke(ottl
[0170] D-amphetamine (0.5, 1 mg/kg) administered before the preference session
induced
the following effects:
[0171] - D-
amphetamine did not significantly modify the difference of distance
travelled in the drug-paired vs. the vehicle-paired compartment:
[0172] 0 In the
two Hero-A groups, the distance travelled was higher in the
drug-paired compartment than in the vehicle-paired compartment
(Figure 1, upper panel).
[0173] o The
difference of distance travelled in the drug-paired vs. the
vehicle-paired compartment was higher in the two Hero-A groups
than in the Control group and not significantly different between
Hero-A groups and the Hero group (Figure 1, lower panel).
[0174] - D-amphetamine at 0.5 mg/kg, but not at 1 mg/kg, tended to
decrease the
time spent in the drug-paired compartment:
[0175] o In the Hero-A. 0.5 group:
[0176] a. The time
spent was not significantly different between the
drug-paired and the vehicle-paired compartment (Figure 2,
upper panel).
[0177] sr The
difference of time spent in the drug-paired vs. the
vehicle-paired compartment was not significantly different
from both the Control group and the Hero group (Figure 2,
lower panel).
[0178] o in the Hero-A I group:
[0179] itt The time
spent was higher in the drug-paired compartment
than in the vehicle-paired compartment (Figure 2, upper
panel).
[0180] a The
difference of time spent in the drug-paired vs. the
vehicle-paired compartment was higher than in the Control
group and not significantly different between from Hero
group (Figure 2, lower panel).
[0181] - D-amphetamine at 0.5 mg/kg, but not at 1 mg/kg decreased the
total distance
travelled in two compartments (Figure 3).
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
26
[0182] Conclusions: These results do not show a reliable effect of D-
amphetamine on the
place preference induced by heroin.
[0183] D-amphetamine (0.5 mg/kg) non-significantly reduced the heroin-induced
increase
of time spent in the drug-paired compartment and had no effect on the heroin-
induced
increase of distance travelled in the drug-paired compartment.
[0184] D-amphetamine (1 mg/kg) did not modify the heroin-induced increases of
time
spent and distance travelled in the drug-paired compartment.
liffdot of Min/Idol on place preferenee mnduce4.by herein
[0185] Mazindol (0.125, 0.25, 0.5, 1 and 2 mg/kg) administered before the
preference
session induced the following effects:
[0186] - Mazindol
(0.125 mg) had no significant effect on the heroin-induced
increases of distance travelled (Figure 1 and of time spent (Figure 2) in the
drug-paired compartment.
[0187] - Mazindol (0.25 mg/kg):
[0188] 0
Significantly reduced the heroin-induced increase of the difference
of distance travelled in the drug-paired vs. in the vehicle-paired
compartment (Figure 1, lower panel), but this effect was partial,
since the Hero-Mz 0.25 group travelled more distance in the drug-
paired than in the vehicle-paired compartment (Figure 1, higher
panel).
[0189] 0 Tended
to reduce the heroin-induced increase of time spent in the
drug-paired compartment: the time spent by the Hero-Mz 0.25
group was not significantly different between the drug paired and
the vehicle-paired compartment (Figure 2, higher panel), was not
significantly different from the Control group but was also not
significantly different from the Heroin group (Figure 2, lower
panel).
[0190] - Mazindol (0.5 mg/kg):
[0191] o
Significantly antagonized the heroin-induced increase of the
difference of distance travelled in the drug-paired vs. in the
vehicle-paired compartment: in the Hero-Mz 0.5 group, the
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
27
distance travelled was not significantly different between the drug-
paired and the vehicle-paired compartment (Figure 1, higher
panel), and the difference of distance travelled in the drug-paired
vs. in the vehicle-paired compartment was lower than the Hero
group and not significantly different between from the Control
group (Figure 1, lower panel).
[0192] o Tended
to reduce the heroin-induced increase of time spent in the
drug-paired compartment: the time spent by the Hero-Mz 0.5 group
was not significantly different between the drug-paired and the
vehicle-paired compartment (Figure 2, higher panel), was not
significantly different from the Control group but was also not
significantly different from the Heroin group (Figure 2, lower
panel).
[0193] - Mazindol (1 mg/kg):
[0194] 0 Did not
significantly reduce the heroin-induced increase of the
difference of distance travelled in the drug-paired vs. in the
vehicle-paired compartment: in the Hero-Mz 1 group, the distance
travelled tended (p = 0.06) to be higher the drug- paired and the
vehicle-paired compartment (Figure 1, higher panel), and the
difference of distance travelled in the drug-paired vs. in the
vehicle-paired compartment was not significantly different from
the Hero group and was higher than the Control group (Figure 1,
lower panel).
[0195] o Did not
significantly modify the heroin-induced increase of time
spent in the drug-paired compartment (Figure 2).
[0196] - Mazindol (2 mg) had no significant effect on the heroin-
induced increases of
distance travelled (Figure 1) and of time spent (Figure 2) in the drug-paired
compartment.
[0197] Mazindol decreased locomotor activity at all doses tested except 2
mg/kg (Figure 3)
[01981 Conclusions. These results show that mazindol (0.25, 0.5 mg/kg)
decreased the
place preference induced by heroin.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
28
[0199] The heroin-induced increase of distance travelled in the drug-paired
compartment
was reduced by mazindol (0.25 mg/kg) and was antagonized by mazindol (0.5
mg/kg). The
distance travelled was not significantly different between the drug-paired and
the vehicle
paired compartment in animals treated with mazindol (0.5 mg/kg), and there was
no
significant difference of time spent in the drug-paired compartment vsõ the
vehicle-paired
compartment in animals treated with mazindol (0.25, 0.5 mg/kg). Mazindol
(0.125, 1 and 2
mg/kg) did not induce modifications of the distance travelled and time spent
in the drug-
paired vs. the vehicle-paired compartments, and therefore did not induce
effects suggesting a
decrease of the place preference induced by heroin.
[0200] Table 5 - Distance travelled in the two compartments, in the vehicle-
paired
compartment, in the drug-paired compartment and in the drug-paired compartment
minus the
vehicle paired compartment and time spent in the vehicle-paired compartment,
in the drug-
paired compartment and in the drug-paired compartment minus the vehicle paired
compartment at the preference session. Statistical analysis. "p drug vs.
vehicle": within each
individual group, p values for the comparisons of the distance travelled and
of the time spent
in the drug-paired compartment vs. the vehicle-paired compartment (two-tailed
paired
Student's). "p vs. Control" and "p vs. Hero": comparison vs. the Control group
and vs. the
Heroin group, respectively, of the total distance travelled and of the
differences of distance
travelled and of time spent between the drug-paired compartment and the
vehicle-paired
compartment, of Heroin groups vs. the Control group (two-tailed unpaired
Student's t test).
CA 03074054 2020-02-27
WO 2019/058172 PCT/IB2018/001138
29
Dee V .- Ptefelertte senien -
............................. - -
............................. 1114.4eM Wel Time- Teel -
Group ---
El ^5g 4 &rya:tree m Compartment
Nur-Vehicle '1
01 0e k"it: e i 0:tr - ' tit.:=kre. ; r..'rm = ' NI.
''''"'"C''
COMM' Ma.3:1 13941. S. 1220;9 7- .4 / 21. / -1P3..6 951.7
1,16. 3 -105.3
ti v13 :: i. :..1 ''..i...,:" 1 .3364 i :5ii5 !i
15?..: . 3? 1 39 1 =i5 2
.---- 0 Ain,ii Vs. ____________________________________ ;;...:. --
______________________________________ ....... __________________
'
- A __
Hero Me an :,--SkV.0 SMS.o 74466 te99.3 725.3
1533.1 :.`..X.µ.4
MI .. 2.74.ii .. '5:i ": 9 :!.7ii
..i.r 9
0;023 OM(
0 v.:. ,.eet.,..:=' s 1147 .. .. , .. .. .1,, ,,,,,,,
i 0.001
.....-=
riur t :,==A ::"..,..; m,1,,,1 79.5 4582.7 ' ' 6707.2 .
11J. 4. 3 sms n4.5 ! 165.9
,
N:.=...] ii...i 6619 3.26.4 f.r.f 9 333.:1 f.A.C:
Cs.1 ':3 i ...:1.9=.
...... i., ::,;:g 1:s ,:f:i.:'
p ;6== CP=1:1,14 5. 0Ø10 ............. CA.+XXX . (os4 . .
a v.t.= RCN 5... ,,,, 0.644 . asle
....... . - .m.......- ---- - " "" "T . - - - . .
Mere-A 1 Mean 13005.6 536.6. 8 7416.1' 1827.8 '$J
.1.01.6.3 1.26S
S345 637 3 ?:i0fi 553.Z .
;24000 VA. vt=c:fAir s 1002? CA A.20
... .. .
"
at e.7
:............,.....-............................. ,, .õ õs, .
1 NC," (,=Mt e.11as mcz.pi .mo.,4 4in. s it 5623.6 1
)417 .3 Cr51. 3 :: MS. 7 110
: ! . .
r4:411 =i=': NI ::6===14, qi...i.:1 2: =::3$=.; i 3 ?ii.
3 Mi 4 64 4 '1316
e Wye, 14. vohe 1
.. .. = t = = . (3.003
P Vs. Commis: 0.001
=
p vs. Hero s af47.1 0.330 = ?'!1-0-.-.- -
.x=Nar ---r=---4.337,,,T,==n,Pr= :..t..-.n......õ,
mprorrnme.w14.................,,,Q,
42 ,,,,, === -:
- Noro.61x-0; 2.5 n
me an 9390.3 . 06.4 .s.l. i 5002.1 - MA fas , 433.6
.
..
Nwli. . 5..E NI 538.8 ................ . 20.0 .... i ,,
46.3
' .. ....--------
p 4I14.1 .vs..=...7 hick., Ct027 a .5171
= = = = = - is ;,. Com, 0! 1 4001 C.M.$
I. T?
OJ
1) V::. %e ,,,, S lam vow
1=:,:ea....:.....v............;
t4e10-613 0.5 M5n.irt 8164.5 3761.8 4111.7 659.0 834.9 =,
M5.1 3"43.1
.. . ......- ..
Na3.1 i'lA ,i2 0 =.:,ii: 4: 5'i7 2 - :4.ii
... . :
P cf,u0 u-S. vrii:,..kr s' ago,
A VS < ft.:i A 0.003 6 0.3i, 0 107
-----
i; V:. ieeyo....= .asto 0...02f.
:,. . __ . .,J,.r---- lc ,,,,,,,,, . ,,,,,,,,,
,,,,, ........ ......... ncr.::,:=sssmr,:c, .. ... =-. .
iircv41441 !Wean. 9746.4 eta.9 - 5444.5, n62.6 714.0
. 1 106.0 aux
...... 3343 SEM 87:A.3 I:. $s.4 CM.2 13..3 63.3 :432
i65..:
p atw n= viVA:Ak. S' VOA. L047 .. = = . .
t= v i.::',,,,N).::=,i s'.. : USX I.
.4=QX = ,..;.,::0; .. _ 1 0 33/
liero.8112 7 MAW) 1.2006.8 S047µ.9 i 7.050.9 1MS 704
1059.7 Z:36.3
to1.2 SEM ' :52 5 c.,-. tc. . 76:...7
cif. 6 ii2.4 .. . .. . . tits"; 124 fi
. = = = = = =
0 dree vi. ,r.61f.i...' s
pz. cishotus. 0 36 am% .1 12403
...................................... : 0.904 0.,:;;',1 ..
.1kttrAbliktigri. Of the place preferetice induced by orzindol
[0201] The results of the preference session are presented in Table 6.
[0202] Mazindol (2 mg/kg), administered before drug sessions induced the
following
effects at the preference session:
[0203] - An increase of the difference of distance travelled in the drug-
paired vs. the
vehicle- paired compartment:
[0204] o In the MAZ 2 group, as well as in the Hero group, but not
in the
Control group, the distance travelled was higher in the drug-paired
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
compartment than in the vehicle-paired compartment (Figure 7,
upper left panel).
[0205] o The
difference of distance travelled in the drug-paired vs. the
vehicle-paired compartment was higher in the MAZ 2 group than
in the Control group and was not significantly different between
the MAZ 2 and the Hero group (Figure 7, upper right panel).
[0206] - An increase of the time spent in the drug-paired vs. the
vehicle-paired
compartment:
[0207] 0 In the
MAZ 2 group, as well as in the Hero group, but not in
control group, the time spent was higher in the drug-paired
compartment than in the vehicle-paired compartment (Figure 7,
lower left panel).
[02081 0 The
difference of time spent in the drug-paired vs. the vehicle-
paired compartment was higher in the MAZ 2 group than in the
Control group and was not significantly different between the
MAZ 2 and the Hero group (Figure 7, lower right panel).
[0209] Conclusions. Mazindol (2 mg/kg) induced a place preference,
[02.10] Mazindol (2 mg/kg) dramatically increased the distance travelled and
the time spent
in the drug-paired compartment comparatively with the vehicle-paired
compartment at the
preference session. These effects were of the same extent as those induced by
heroin (1,25
mg/kg),
[0211] Table 6. Distance travelled in the two compartments, in the vehicle-
paired
compartment, in the drug-paired compartment and in the drug-paired compartment
minus the
vehicle paired compartment and time spent in the vehicle-paired compartment,
in the drug-
paired compartment and in the drug-paired compartment minus the vehicle paired
compartment at the preference session. Statistical analysis. "p drug vs.
vehicle": within
each individual group, p values for the comparisons of the distance travelled
and of the time
spent in the drug-paired compartment vs. the vehicle-paired compartment (two-
tailed paired
Student's). "p vs. Control" and "p vs. Hero": comparison vs. the Control group
and vs. the
Heroin group, respectively, of the total distance travelled and of the
differences of distance
travelled and of time spent between the drug-paired compartment and the
vehicle-paired
compartment, of Heroin groups vs. the Control group (two-tailed unpaired
Student's t test).
CA 03074054 2020-02-27
WO 2019/058172
PCT/I132018/001138
31
Day 12- Preference session
Distance (cml Time isec)
Group
Drug + Compartment Compartment
Drus-Vehicle
Vehicle Vehicle Drug Drug-Vehlcle
Vehicle Drug
Control Mean 13431.6 7225.3 6206.4 -101*0. 975.8
8242 -151.5
N..12 ........ SEM 423.6 450.3 373.1 721;7 t5
55.0 112.0
o arug vs. vehkle s a1136 0.20$
Hero Mean 13647.5 5728.4 7919.1. 2196.6 737.0
1061.0
N.12 SEM St ;.3 57.7.5
45.9570.$ 237
p drug vs. vehicle 0001 CAW
vs. control s L. 0.001 ............ i
0.046
810.2 2 ....... Mean 14858.2 5845.2 00110 3167.8
. 722.7 1077,3
354.6
N.12 SEM 571.5 3322 678 1
0 drug vs. vehicle S 0.001 0.001
p vs. controls 0.057 0401 ft00.1,
1 o vs. HEMS .. 0.237 , 0.282 I D.Z3Z6
Ntil())011(t prtci.Otated withdrawal syndrome of heroin
[0212] The results are presented in Table 7.
[0213] Heroin induced an increase of the global score (Figure 4) and of the
scores for
weight loss, escape attempts, wet dog shake (Figure 5), diarrhea, facial
fasciculation or teeth
chattering and profuse salivation (Figure 6).
[0214] Heroin also non-significantly increased the scores for abdominal
constrictions and
chromodacryorrhea.
[0215] 1)-amphetamine (1 mg/kg) did not reduce the global score (Figure 4) and
the
different withdrawal symptoms (Figure 5)(Figure 6). Conversely, D-amphetamine
tended to
increase on symptom, the chromodacryorrhea. This increase was not significant
probably
because of the small number of subjects in the amphetamine group.
[0216] Mazindol:
[0217] - Reduced the global score; this effect was significant at all
doses except
0.125 mg/kg (Figure 4).
[0218] - Reduced the scores for wet dog shake (significant effect at I
and 2 mg/kg)
(Figure 5) facial fasciculation or teeth chattering (significant at 2 mg/kg)
and
profuse salivation (significant at all doses except 2 mg/kg) (Figure 6).
[0219] - Did not significantly reduce the scores for weight loss and
escape attempt,
which was, to the contrary, increased by mazindol (2 mg/kg) (Figure 5) and
diarrhea (Figure 6).
[0220] Conclusions. Mazindol reduced the withdrawal symptoms of heroin.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
32
[0221] Mazindol decreased the naloxone precipitated withdrawal symptoms of
heroin.
This effect was significant at 0,25, 0,5, 1 and 2 mg/kg, but not at 0,125
mg/kg. D-
amphetamine at 1 mg/kg did not reduce the withdrawal symptoms of heroin.
[0222] Table 7 - Naloxone precipitated withdrawal syndrome of heroin. 1:
global score
and scores for the different symptoms, 2: weight loss, 3: escape attempts, 4:
abdominal
constrictions, 5: wet dog shakes, 6: diarrhea, 7: facial fasciculation or
teeth chattering, 8:
swallowing movements, 9: profuse salivation, 10: chromodaeryorrhea, 11:
ptosis, 12:
abnormal posture, 13: erection or ejaculation and 14: irritability.
Statistical analysis.
Difference vs. Saline group or vs. _Hero group: p values (Mann-Whitney LT
test).
. ________ ,
..,:>' c. .., d, 7' v. / ,,.. ,,' c"-'''' ,''. ,,
," c'<''. ==µµ 41',"1 4... /1 A ===== .:;' --'.. =)1 ''.. ''> .'" ...`= fr:
'41' ,c e .."' ===== ...t, = = N.: .' .' / .:::' ,-' ' .." sµ ,
. ' / :..>' . ' c:`= / c> / 0 / =,'
................ " 1..^ / .)). S t'S , =.µ C":.'
./ A. = S %V". ':. / '= ., '. ." V / 'i = :,' '=-
' .................................................. t .:' 4-----.
Sai1ne Mean 0.8 : 0.0 0.0 0.0 0.8 0.0 i 0.0
0.0 0.0 0.0 0.0 i 0,0 i, 0.0 1 0.0
o3 SEM , o.s: 0.0 0.0 = 0.0 0 S 0 :I: i 0 0 0 0
..i, 0,0 õ._. 0.0 ao ao o.o
4-. ______________________
............................................... _ .
Hero Mean 22,4 1.9 i 1,1 4,1 3,4 2.0 2.0 0.9
5.5 1.1 0.1 ; 0.2 I 0.0 i 0.0
0.8 2., 0.3 0.0 0.0 0.3 0 3 0.5
OA 0.2 1 0,0 1, 01
I p vs. Sail, I 0.e)01 0,002 [ 0.02 1-
0.5 ' 0,004 am 1 0.001. 07 0.0,3 0.5 03 0.3 1 1
r ................. c ____________ -
I
, I-- .------i-:
,Amph 1 Mean 22.5 2.0 _1,13 0.0 3 5 ..,0 1. 2.0 1.0
I 5.3 5,0 ' 0,0 0,0 1 0.0 0.0
S .4 S CM 3 0 04 0.5 . 0.0 c.:=-, ,'= ..= 0.0 0.6 1.3
0.0,1 0.0 0.0 0.9_1, 01 i
o v Hero 0.5 0,8 0.4 or 1 i __ 1 09 ' 0.06
09 a.9 1 1
+ 2.. :
-
,
1. Ma 0.12S Mean 182
0.3 o.3 1 f...,.: aof.; a i..; 12). 5
1,a02 ,I.: 5 0.9 0.9 1 1 1
Mel 0.25 Mean 8.3 1.2 0.7 0.0 1.7 1 0 2.0
,L1.0 [ 0.0 0.8 .I_ 0.0 0,0 i 0.0 0.0
: n .- 6 SEM ., 2,2 0.7 03 0.0 g :.12 0.0
1.1:,, i 0.0 0.3 0.0 0.0 0.0 0.0
p vs, Hero 0.02 C .; 0.4 0.5 0.09 fI4 i ::
1 ;-. .'-' 1 0.007 0.900a 3 1 1
..
3 -1. .. 1
Maz 0,5 Esit, 9,.7 17 1.7 0.0 3 i .0 1 0
,I..0 I 0 .3 ; ao 0.0 ao 01 rim Dm
.. n=6 sEivi 1,6 0.µ,. o.6 ao ..i.-i i,.-.:
.2.0 o Q 1 01om om .J, rim
- ,
P '--. Hero awl a..3 a 4 a 3 07 a. .;= [ .1. ...:: 4
. 0.007 0509
1 .. ....................................
.Z.---,---- ..................................... - - h- = __ i
_ ...........
Maz 1 Mean 14.0 3.2 2.5 0.0 1.0 1.7 2,0 0.3
1,2 1.7 0.0 0.0 0.:5 1 0.0
t , i
, = 6 ,,,,=i t t '4' 0.S I.),3 0.0 0.7 0.3 rho
12 , 1.2 i .L1 0.0 0.0
, 0.03 0,1 (102 I 0.5 0,02 0.6 I 1. 0.4 I
004 I,
iln 0 7 a 9 a9 O. !.d. .1
k 2 Mean 10.4 : 3.0 , 1.6 0 0 0.4 2.0 1 0.4 0,0 1
1.4 1.0 5 5 1 0 6 0.0 0.0 '
[ n .. S. SEM , .Ete4 :: 0,9 ': 0.5_ 0.0 ;
:),', i 0.0 . 0,4 I 0.0i 1.4 k, 1.0 0.0 i 0.:1, 0.0 ' 0.9 :
L___ p vs. dem 0,02 " t1.3 05 0.5 0.005 L 1
0.01 [02 0.06 1 1
1
REFERENCES
(1) http://www.pewtrusts.orgi-linedia/assets/20 I 5/03/su bstanceusedi
sordersandthero I eoft
hestates.pdf Last accessed 1 September 2017,
(2) https://www.businessgrouphealth ,orglpublf3151957-2354-d714-5191-e 1
1a80a07294
Last accessed 1 September 2.017.
(3) Bremer PT, et al.: Development of a Clinically Viable Heroin Vaccine.
,./. Am. Chem.
CA 03074054 2020-02-27
WO 2019/058172
PCT/IB2018/001138
33
Soc. 2016;139(25)8601-8611.
(4) Hadler .1: Mazindol, a New Non-Amphetamine Anorexigenic Agent. or Clin
Pharmacology. 1972;12(11):453-45.
(5) Kim SS, Lee H'W, Lee KT: Validated method for determination of mazindol
in human
plasma by liquid chromatography/tandem mass spectrometry. Chromatogr B Analyt
Teohnol Biomed Life Sci. 2009;8771011-16.
(6) Selby] JP, et al.: Mazindol and cocaine addiction in schizophrenia.
Biol Phsychiatty.
1992;31:1172-1183.
(7) Stine SM, et al. Mazindol treatment for cocaine dependence, Drug
Alcohol Depend.
1995 ;39(3):245-52.
(8) Margolin A, et al. Mazindol for relapse prevention to cocaine abuse in
methadone-
maintained patients. Am Jr Drug Alcohol Abuse. 1995;21(4)469-81,
(9) Schlussman SD, Zhang Y, Hsu NM, Allen JM, Ho A, Kreek MI Heroin-induced
locomotor activity and conditioned place preference in C57BL/6.1 and 129P31.1
mice.
Neurosci Lett. 2008; 440(3):284-8.
(10) Jiang Li-I, Wang J, Wei XL, Liang QY, Cheng 'IT. Exogenous sodium
hydrosulfide
can attenuate naloxone-precipitated withdrawal syndromes and affect cAMP
signaling
pathway in heroin-dependent rat's nucleus accumbens. Eur Rev Med Pharmacol
Sci.
2012;16(14):1974-82.
(11) Gellert VF, Holtzman SG. Development and maintenance of morphine
tolerance and
dependence in the rat by scheduled access to morphine drinking solutions. or
Pharmacol Exp Then 1978;205:536-546.
(12) Robeldo-Gonzalez et al. Repeated administration of mazindol reduces
spontaneous
pain-related behaviors without modifying bone density and microarchitecture in
a
mouse model of complete Freund's adjuvant-induced knee arthritis. Journal of
Pain
Research 2017:10 1777-1786,
